Cencora, Inc. reported strong financial results for its fiscal year 2025 third quarter ended June 30, 2025. Revenue increased 8.7% year-over-year to $80.7 billion. Adjusted diluted EPS rose 19.8% to $4.00 in the fiscal third quarter, compared to $3.34 in the prior year.
The U.S. Healthcare Solutions segment continued its robust performance, with revenue increasing 8.5% to $72.9 billion and operating income up 29.1% to $0.9 billion, driven by increased product sales and the RCA acquisition. The International Healthcare Solutions segment, however, saw operating income decrease 12.9% to $156.2 million.
Cencora updated its fiscal year 2025 adjusted diluted EPS guidance, raising it to a range of $15.85 to $16.00, up from the previous range of $15.70 to $15.95. The company also declared a quarterly cash dividend of $0.55 per common share, payable September 3, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.